MIRA Pharmaceuticals Advances MIRA-55 Toward Q1 2027 IND
MIAMI, September 1, 2026 MIRA Pharmaceuticals, Inc. has reported positive results from completed 7-day dose-range finding toxicology and toxicokinetic...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MIAMI, September 1, 2026 MIRA Pharmaceuticals, Inc. has reported positive results from completed 7-day dose-range finding toxicology and toxicokinetic...
